<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7499491</article-id><article-id pub-id-type="pmid">32829400</article-id><article-id pub-id-type="doi">10.1093/cid/ciaa1223</article-id><article-id pub-id-type="publisher-id">ciaa1223</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Chaisemartin</surname><given-names>Cl&#x000e9;ment</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="c1"/><!--<email>clementdechaisemartin@ucsb.edu</email>--></contrib><contrib contrib-type="author"><name><surname>de Chaisemartin</surname><given-names>Luc</given-names></name><degrees>PhD, PharmD</degrees><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Department of Economics, University of California, Santa Barbara</institution>, Santa Barbara, CA 93106, <country country="US">USA</country></aff><aff id="AF0002"><label>2</label>
<institution>Immunology Department, APHP.Nord-Universit&#x000e9; de Paris, Bichat Hospital</institution>, Paris, <country country="FR">France</country></aff><aff id="AF0003"><label>3</label>
<institution>Universit&#x000e9; Paris-Saclay, Inserm, &#x0201c;Inflammation, microbiome, immunosurveillance&#x0201d;</institution>, Ch&#x000e2;tenay-Malabry, <country country="FR">France</country></aff><author-notes><corresp id="c1">Corresponding Author: Cl&#x000e9;ment de Chaisemartin; E-mail: <email>clementdechaisemartin@ucsb.edu</email>, Telephone: +1-805-452-9642.</corresp></author-notes><pub-date pub-type="epub" iso-8601-date="2020-08-23"><day>23</day><month>8</month><year>2020</year></pub-date><elocation-id>ciaa1223</elocation-id><history><date date-type="received"><day>30</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2020</copyright-year><license license-type="publisher-standard" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model"><license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model</ext-link>)</license-p></license><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri xlink:href="ciaa1223.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The Bacille Calmette-Gu&#x000e9;rin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against COVID-19. Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Sweden in 1975, where discontinuation of newborns BCG vaccination led to a dramatic fall of the BCG coverage rate, thus allowing us to estimate the BCG&#x02019;s effect without the biases associated with cross-country comparisons.</p></sec><sec id="s2"><title>Methods</title><p>Numbers of COVID-19 cases and hospitalizations were recorded for birth cohorts born just before and just after 1975, representing 1,026,304 and 1,018,544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. This method used on such a large population allows for a high precision that would be hard to achieve using a randomized controlled trial.</p></sec><sec id="s3"><title>Results</title><p>The odds ratio for Covid-19 cases and Covid-19 related hospitalizations were 1&#x000b7;0005 (CI95: [0&#x000b7;8130-1&#x000b7;1881]) and 1&#x000b7;2046 (CI95: [0&#x000b7;7532-1&#x000b7;6560]), allowing us to reject fairly modest effects of universal BCG vaccination. We can reject with 95% confidence that universal BCG vaccination reduces the number of cases by 19% and the number of hospitalizations by 25%.</p></sec><sec id="s4"><title>Conclusions</title><p>While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19 among middle-aged individuals.</p></sec></abstract><kwd-group><kwd>Covid-19</kwd><kwd>BCG</kwd><kwd>Regression discontinuity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>article-lifecycle</meta-name><meta-value>PAP</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta></custom-meta-group></article-meta></front></article>